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BACKGROUND AND PURPOSE
3-iodothyronamine (T1AM) is a metabolite of thyroid hormone acting as a signalling molecule via non-genomic effectors and
can reach intracellular targets. Because of the importance of mitochondrial F0F1-ATP synthase as a drug target, here we
evaluated interactions of T1AM with this enzyme.
EXPERIMENTAL APPROACH
Kinetic analyses were performed on F0F1-ATP synthase in sub-mitochondrial particles and soluble F1-ATPase. Activity assays and
immunodetection of the inhibitor protein IF1 were used and combined with molecular docking analyses. Effects of T1AM on
H9c2 cardiomyocytes were measured by in situ respirometric analysis.
KEY RESULTS
T1AM was a non-competitive inhibitor of F0F1-ATP synthase whose binding was mutually exclusive with that of the inhibitors
IF1 and aurovertin B. Both kinetic and docking analyses were consistent with two different binding sites for T1AM. At low
nanomolar concentrations, T1AM bound to a high-affinity region most likely located within the IF1 binding site, causing IF1
release. At higher concentrations, T1AM bound to a low affinity-region probably located within the aurovertin binding cavity
and inhibited enzyme activity. Low nanomolar concentrations of T1AM increased ADP-stimulated mitochondrial respiration in
cardiomyocytes, indicating activation of F0F1-ATP synthase consistent with displacement of endogenous IF1,, reinforcing the in
vitro results.
CONCLUSIONS AND IMPLICATIONS
Effects of T1AM on F0F1-ATP synthase were twofold: IF1 displacement and enzyme inhibition. By targeting F0F1-ATP synthase
within mitochondria, T1AM might affect cell bioenergetics with a positive effect on mitochondrial energy production at low,
endogenous, concentrations. T1AM putative binding locations overlapping with IF1 and aurovertin binding sites are described.
Abbreviations
DmH+, proton motive force; ASp, AS particles;; IF1, F0F1-ATP synthase inhibitor protein; Ki inhibition constant; SMP,
Mg-ATP sub-mitochondrial particles; T1AM, 3-iodothyronamine
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Introduction
3-iodothyronamine (T1AM) is a recently discovered metabo-
lite of thyroid hormone that is thought to derive from thy-
roxine as a result of enzymatic deiodination and
decarboxylation (Scanlan et al., 2004; Zucchi et al., 2010). It
has been proposed to act via non-genomic effectors as a
signalling molecule that can rapidly influence several physi-
ological manifestations of thyroid hormone action, including
thermal homeostasis (Scanlan et al., 2004), fuel metabolism
(Braulke et al., 2008), hormone secretion (Regard et al., 2007;
Klieverik et al., 2009) and neuronal function (Snead et al.,
2007). Administration of exogenous T1AM in vivo at micro-
molar concentrations produces immediate bradycardia and
reduced cardiac output, thereby providing evidence of a new
aminergic system that modulates cardiac function (Chiellini
et al., 2007). In addition, in isolated hearts, T1AM decreased
cardiac contractility and increased the resistance to ischemic
injury. Contractile effects have been attributed to reduced
sarcoplasmic reticulum calcium release (Ghelardoni et al.,
2009). Cardioprotection occurs at T1AM concentrations
which are much lower than those able to affect contractile
function and it has been not associated with any evidence of
altered calcium homeostasis, while pharmacological evidence
suggests a potential role of mitochondrial effects (Frascarelli
et al., 2011), although the detailed mechanisms remain to be
elucidated.
Endogenously produced T1AM has been detected in vivo
at nanomolar concentrations in several rat tissues, in mouse
brain, as well as in human, rat, mouse and guinea pig blood
(Saba et al., 2010). T1AM interacts with the trace amine-
associated receptor 1 (TAA1), a member of a novel family of
membrane G-protein coupled receptors (GPCRs) (Zucchi
et al., 2006; Grandy, 2007; receptor nomenclature follows
Alexander et al., 2011). The action of T1AM at extracellu-
larly accessible targets, such as TAA1, is terminated by its
uptake into cells, which involves multiple transporters that
control the intracellular distribution of the compound (Ian-
culescu et al., 2009). This transport gives T1AM access to
potential intracellular targets, such as the vesicular
monoamine transporter VMAT2 (Snead et al., 2007) and
mitochondrial proteins (Frascarelli et al., 2011; Venditti
et al., 2011). Therefore, identifying additional intracellular
targets of T1AM may have physiological and pharmacologi-
cal importance.
F0F1-ATP synthase is a multi-subunit, membrane-
associated protein complex that catalyses the phosphoryla-
tion of ADP to ATP at the expense of a proton-motive force
generated by an electron transport chain in energy-
transducing membranes (Boyer, 1997; Stock et al., 2000; Ped-
ersen, 2007; Watt et al., 2010). The mitochondrial enzyme
comprises a globular F1 catalytic domain (subunit composi-
tion: a3b3gde), termed F1-ATPase when isolated, and a
membrane-bound F0 proton translocating domain, linked
together by central (Gibbons et al., 2000) and peripheral
stalks (Dickson et al., 2006; Rees et al., 2009).
The crystal structures of F1-ATPase demonstrate that the a
and b subunits of the F1 domain are structurally similar, and
each subunit consists of three domains: a small N-terminal
domain, a nucleotide binding domain and a helical
C-terminal domain (Abrahams et al., 1994; Capaldi and
Aggeler, 2002; Leyva et al., 2003). Both a and b subunits bind
nucleotides, but only the b subunit participates in catalysis.
Because of the asymmetry of the g-subunit, the catalytic
b-subunits adopt different conformations with different
nucleotide occupancies. Two of the b-subunits are designated
bDP and bTP, while the third has no bound nucleotide and is
thus referred to as ‘empty’ and designated bE (Abrahams et al.,
1994). The structures of F1-ATPase provided insight into the
binding change mechanism: the interconversion of the dif-
ferent b-subunit conformations was proposed to occur during
the catalytic cycle due to rotation of the central stalk (Abra-
hams et al., 1994; Capaldi and Aggeler, 2002; Leyva et al.,
2003).
The activity of F0F1-ATP synthase is regulated by ADP, the
proton motive force (Dm+) and by its natural inhibitor
protein, IF1 (Harris and Das, 1991) – a basic amphiphilic
protein of 84 amino acids (Green and Grover, 2000) that
acts as a non-competitive inhibitor by binding to the F1
domain with a 1:1 stoichiometry. Binding is regulated by
physiological levels of ATP, Ca2+ and Mg2+ (Hong and Peder-
sen, 2008; Johnson and Ogbi, 2011). Moreover, low pH and
Dm+ (Lippe et al., 1988), and the hydrolysis of Mg-ATP
(Rouslin, 1983) promote the formation of the inhibited
IF1–F1 complex, while higher pH and Dm+ displaces IF1 from
its inhibitory site (Hassinen et al., 1998). As resolved from
high-resolution crystallography, IF1 binds to a site at the
catalytic interface between the C-terminal domains of the
aDP- and bDP-subunits (Cabezon et al., 2003; Bason et al.,
2011), and it detaches from this site upon enzyme rotation
and conversion of the b subunits during ATP synthesis (Gle-
dhill et al., 2007b). IF1-mediated inhibition is widely
accepted to be essential during myocardial ischemia, when
F0F1-ATP synthase switches from ATP synthesis to ATP
hydrolysis (Rouslin, 1983; Harris and Das, 1991), as well as
in ischaemic and pharmacological preconditioning (Con-
tessi et al., 2004; Grover et al., 2006; Comelli et al., 2007).
More recent data indicate that IF1 can regulate mitochon-
drial F0F1-ATP synthase function and supra-molecular organi-
zation under both physiological and pathological conditions
(García et al., 2006; Campanella et al., 2008), and that vari-
ations in IF1 expression level may play a significant role in
defining resting rates of ROS generation and in regulating
autophagy (Campanella et al., 2009; Hall et al., 2009). Dis-
covery of additional natural factors able to affect the IF1
steady-state binding to F0F1-ATP synthase may contribute to
highlight such processes.
Several covalent and non-covalent inhibitors of mito-
chondrial F1-ATPase have been identified and the study of
their kinetics, together with the biophysical localization of
their binding sites, has helped to clarify the catalytic mecha-
nism of the enzyme. In addition to the IF1 binding site men-
tioned above (Gledhill et al., 2007b), high-resolution
crystallography has led to the identification of four inhibitory
sites: the polyphenolic phytochemicals site, the catalytic site,
the aurovertin site and the efrapeptin binding site (Abrahams
et al., 1994; van Raaij et al., 1996; Menz et al., 2001; Kagawa
et al., 2004; Gledhill et al., 2007a). Depending on experimen-
tal conditions, the antibiotic aurovertin has been found to
exert uncompetitive, non-competitive or partial mixed inhi-
bition of both ATP hydrolysis and synthesis (Johnson et al.,
2009), while the polyphenolic inhibitors, piceatannol and
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resveratrol, exhibit non-competitive and mixed inhibition
respectively (Bullough et al., 1989; Zheng and Ramirez, 1999;
2000).
Over recent years, F0F1-ATP synthase has been highlighted
as a molecular target for drugs aimed at the regulation of
energy metabolism and the treatment of various diseases,
such as autoimmune and immune disorders (Hong and Ped-
ersen, 2008; Johnson and Ogbi, 2011). In this field, some
benzodiazepine-based inhibitors of F0F1-ATP synthase (BMS
compounds) selectively inhibit ATP hydrolase activity and
the ATP decline during ischemia, while not affecting ATP
production in normoxic and reperfused hearts (Grover and
Malm, 2008). Moreover, the presence of F0F1-ATP synthase on
the surface of several animal cell types has been suggested,
indicating that the enzyme is linked to multiple cell proc-
esses, including lipid metabolism, intracellular pH regulation,
angiogenesis and programmed cell death (see Champagne
et al., 2006). F0F1-ATP synthase is also a target of antimicrobial
agents; for example in Mycobacterium, two mutations in its
c-subunit confer resistance to the new anti-tuberculosis drug
diarylquinoline (Cole and Alzari, 2005). Thus, the develop-
ment of new F0F1-ATP synthase-directed agents has been
encouraged.
The aim of the present work was to investigate whether
T1AM interacts with F0F1-ATP synthase, and to characterize
the effects of such an interaction upon enzyme activity taking
advantage of kinetic and crystallographic data of natural
dietary stilbene polyphenolic compounds and aurovertin B.
To do so, kinetic analyses of the interaction of T1AM with
F0F1-ATP synthase in bovine heart mitochondrial membranes
and F1-ATPase in solution were combined with the modelling
of F1-ATPase structures, leading to the generation of a model
of T1AM binding locations on the F1 domain and the eluci-
dation of the T1AM mechanism of action. We suggest that
T1AM may target F0F1-ATP synthase within mitochondria, as
confirmed when applied to heart-derived cells, and elicit a
twofold effect on the enzyme (IF1 displacement and activity
inhibition), thereby affecting cell bioenergetics.
Methods
Sub-mitochondrial particle preparation
Heavy-layer mitochondria from bovine hearts (obtained from
an abattoir) were prepared in the absence or presence of
succinate and were used to prepare type I and type II MgATP
sub-mitochondrial particles (SMP) respectively (Ferguson
et al., 1977). AS particles (ASp) were obtained by removing IF1
from heavy-layer bovine heart mitochondria by high pH
treatment followed by gel filtration chromatography (Vadi-
neanu et al., 1976). All particle preparations were stored at
-80°C for later use.
As previously reported (Ferguson et al., 1977), type I SMP
(containing IF1-rich F0F1-ATP synthase) showed a specific
ATPase activity of 2.5  0.3 U·mg-1, while type II SMP
(depleted of IF1) showed a greater activity, 5  0.2 U·mg-1.
ASp showed the highest value of ATPase activity, 13 
0.4 U·mg-1.
Particle protein concentration was assayed using the
Lowry method (Lowry et al., 1951) with BSA as standard.
Purification and preparation of proteins
The soluble F1 sector of F0F1-ATP synthase (F1-ATPase) was
isolated from bovine heart mitochondria as described by
Horstman and Racker (1970) then passed through an
XK16/40 Superdex 200pg column equilibrated with 20 mM
Tris/HCl pH 8.5, 200 mM NaCl, 1 mM ATP, 1 mM EDTA and
5 mM 2-mercaptoethanol buffer according to Abrahams et al.
(1994). IF1 was purified from the same source as reported in
Gomez-Fernandez and Harris (1978). The purity of the prepa-
rations was analysed by SDS-PAGE (see Laemmli, 1970). Con-
centrations of F1-ATPase and IF1 protein were assayed by the
bicinchoninic acid method described by Smith et al. (1985)
with BSA as standard.
Inhibition assay
F0F1-ATP synthase activity was measured after incubation
with various concentrations (0–90 mM) of T1AM or resvera-
trol as an internal control using an ADP- or ATP-
regenerating system for ATP synthase or ATPase activity
respectively. To determine the minimal incubation times
that permitted the establishment of equilibrium between
the free enzyme and inhibitor with the enzyme-inhibitor
complex, enzyme activity was measured as a function of
time. These experiments showed that the steady-state con-
dition was reached after 20 min, thus an incubation time of
25 min was applied in all experiments. Preliminary experi-
ments run at the final concentrations achieved in the
cuvette were carried out and showed that the equilibrium
was maintained.
After incubation at pH 7.4, the activity assays were per-
formed by addition of either 40mg SMP or ASp or 2 mg puri-
fied bovine F1-ATPase to 1 mL of assay mixture at 37°C and
following the changes in absorbance of NADPH or NADH at
340 nm. Initial rates (v) over a 60 s period were recorded.
The ATP synthase assay mixture contained 10 mM HEPES
pH 7.4, 20 mM succinate (i.e. the substrate of complex II in
the respiratory chain that sustains the mitochondrial mem-
brane potential Dy), 20 mM glucose, 3 mM MgCl2,
4.78 units·mL-1 hexokinase, 2.2 units·mL-1 glucose-6-
phosphate dehydrogenase, 10 mM KH2PO4, NADP+
0.75 mM, 11 mM AMP and 1 mM ADP (Cross and Kohl-
brenner, 1978). The ATPase assay mixture contained
100 mM Tris/HCl pH 7.4, 50 mM KCl, 6 mM MgCl2, 0.2 mM
EDTA, 15 units·mL-1 pyruvate kinase, 15 units·mL-1 lactate
dehydrogenase (Sigma), 0.23 mM NADH, 1 mM phos-
phoenolpyruvate and 4 mM MgATP (Zheng and Ramirez,
1999). When SMP and ASp were used, the ATPase assay
mixture also contained rotenone (0.01 mg/mL), a complex I
specific inhibitor, so that the enzyme could only hydrolyse
ATP.
Oligomycin, a polyketide inhibitor of ATP synthesis and
hydrolysis, which binds to the F0 part of the complex, was
used as a control in most of the kinetic analyses to determine
the activity elicited by the assembled F0F1 complex, which
represents around 90–95% of total activity in the mitochon-
drial particles.
IC50 is defined as the amount of T1AM required for 50%
inhibition. Separate measurements made in the presence of
MgADP showed that the inhibitors had no effect on the
coupled assay systems.
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Multiple inhibition kinetics for analysis of
F1-ATPase-T1AM interaction
To evaluate whether T1AM competition with a second inhibi-
tor occurs on the F1-ATPase, the Yonetani–Theorell plot was
used (Yonetani and Theorell, 1964). Specifically, T1AM com-
binations with IF1, resveratrol or aurovertin B were analysed.
The semi-generalized formula shown below for a single
enzyme multiple inhibition system by two reversible inhibi-
tors was applied, where vi and v0 are the velocities of the
inhibited and uninhibited reactions respectively (Martinez-
Irujo et al., 1998).
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It follows that for situations where the binding of two
inhibitors [I1, I2] to the enzyme is mutually exclusive, a plot of
v0/vi against [I1] at a range of fixed [I2] would give a series of
parallel lines. On the other hand, if they can bind simulta-
neously to the enzyme, the slope will change with changing
[I2], and the series of lines will intersect.
IF1 quantification by Western blot analysis in
different SMP preparations and after
treatment with inhibitors
Aliquots of IF1-rich type I SMP were incubated with T1AM (up
to 150 mM; 3.75 mmol·mg-1), resveratrol (21 mM;
0.52 mmol·mg-1) or aurovertin (0.1 mM; 2.5 nmol·mg-1) for
15 min at 37°C and ATPase activity assayed. Reactions were
stopped by ultracentrifugation, the supernatant completely
removed and SMP suspended for immunoblot analysis.
For the quantification of IF1 content (for methods, see
Tomasetig et al., 2002), ASp, type I and II SMP and type I SMP
after treatment with inhibitors were separated by electro-
phoresis in a 15% SDS–polyacrylamide gel under reducing
conditions. Proteins were transferred to nitrocellulose mem-
branes, which were then incubated at room temperature for
1.5 h in 3% non-fat dry milk in PBS containing 0.1% Tween
20 (PBS–Tween). The membranes were incubated overnight at
4°C in PBS–Tween containing 3% non-fat dry milk with
mouse anti-IF1 (1:2000) or mouse anti-b (1:3000) (Mito-
sciences, Cambridge, UK). The membranes were washed three
times in PBS–Tween and incubated in HRP-conjugated goat
anti-mouse IgG (1:10 000). The membranes were rinsed in
PBS–Tween, incubated with Pierce SuperSignal Dura chemi-
luminescence substrate and visualized with Image Scanner
(Amersham). Signal intensities were quantified using Image-
Quant TL program (GE Healthcare, Little Chalfont, Bucking-
hamshire, UK). Densitometric measurements were performed
by Chemi doc XRS and analysed by Quantity One 4.2.1
Software (Biorad).
To determine the ratio between IF1 and b subunits after
treatment with different inhibitors, four quantities of each
type I SMP sample (control and inhibitor treated) were simul-
taneously loaded into a gel and immunoblotted. A linear
relationship was confirmed in each case between increasing
band intensity and the quantities of proteins loaded into the
gel, confirming non-saturating conditions. Quantitative data
were inferred on the basis of the slope of the straight lines
and reported as % of IF1 against b subunit ratio with the
control ratio taken as 100% (Contessi et al., 2007). The results
from four gels are expressed as means (SD).
In situ analysis of ADP-stimulated
respiration in cardiomyocytes by
high-resolution respirometry
Rat cardiomyoblast-derived H9c2 cells (ATCC CRL1446), pur-
chased from the American Type Culture Collection (Rock-
ville, MD, USA) were grown as described by Comelli et al.,
2011. Oxygen consumption was measured by high-resolution
respirometer Oxygraph 2k (Oroboros Instruments, Innsbruck,
Austria) and expressed as pmol (106 s)-1. H9c2 cells (1 ¥
106 cells·mL-1) were re-suspended in respiration buffer
(80 mM KCl, 10 mM Tris-HCl, 3 mM MgCl2, 1 mM EDTA,
5 mM KH2PO4 pH 7.4) and permeabilized by digitonin
(optimal concentration of 3.5 mg per 106 cells). After 10 min
of incubation with T1AM at 37°C, saturating quantity of
glutamate (10 mM), malate (5 mM) (resting respiration) and
ADP (5 mM) (ADP-stimulated respiration) were added to the
chamber. Cytochrome c (10 mM) was added in a parallel
experiment to test for the intactness of the mitochondrial
outer membrane in digitonin-treated cells. Data were digitally
recorded using DatLab4 software (Oroboros); oxygen flux was
calculated as the negative time derivative of oxygen concen-
tration, cO2(t). Before performing the assays, air calibration
and background correction were performed according to the
manufacturer’s protocol. The oxygen level was maintained
above 40% air saturation.
Docking analysis
Docking of the ligand T1AM on F1-ATPase was performed
using the program Autodock Vina (Trott and Olson, 2010).
The docking box was adjusted depending on the structure
used for docking and had average dimensions of approxi-
mately 110 ¥ 110 ¥ 110 Å.
The starting receptor/target structures were taken from
the Protein Data Bank corresponding to the apo form (i.e.
ground state) of F1-ATPase (pdb id. 1H8E, Abrahams et al.,
1994), F1-ATPase bound to aurovertin B with ligand and all
heteroatoms removed (pdb id. 1COW, van Raaij et al., 1996),
F1-ATPase bound to resveratrol with ligand and all heter-
oatoms removed (pdb id. 2JIZ Gledhill et al., 2007a) and
F1-ATPase bound to inhibitor IF1 with ligand and all heter-
oatoms removed (pdb id. 2V7Q, Gledhill et al., 2007b).
All forcefield parameters for T1AM (and for resveratrol
and aurovertin B, for testing the docking procedure) were
assigned using the program AutoDockTools (Morris et al.,
2009), starting with files in sdf format downloaded from the
Pubchem database (URL: http://www.ncbi.nlm.nih.gov/).
Rotatable bonds in the ligands were also assigned using the
program AutoDockTools.
Two docking simulations were performed with aurovertin
B and resveratrol in order to check whether the correctly
bound form could be recovered from the best poses generated
by simulation.
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The exhaustiveness parameter, which controls the extent
of conformational search in the program Vina, was raised to
from 9 (default) to 50. The nine best poses were rotated such
that they were placed in three approximately symmetrical
positions in the ternary complex of ab dimers. For the simu-
lation with resveratrol, the centre of one of the poses was
0.2 Å distant from the centre of the original resveratrol
binding, while for aurovertin B, one of the poses had a 0.5 Å
centre-to-centre distance. The best poses were found for the
original complex with the ligand removed.
For T1AM, the distance of the centre of mass of each pose
from the centre of mass of aurovertin B and resveratrol was
used as a criterion to identify common binding sites. On the
contrary, due to the large extension of IF1 in comparison with
T1AM, the distance between the centres of mass is not sig-
nificant. The maximum number of common atoms contacted
by the ligands and IF1 was considered instead.
Data analysis
Data are shown as meansSD, unless otherwise stated. Sig-
nificant (P < 0.05) differences between group means were
determined using the non-parametric two-tailed Student’s
t-test.
Materials
The phytochemicals, piceatannol and resveratrol (CalBio-
chem, Nottingham, UK), oligomycin and aurovertin B
(Aldrich, Milwaukee, WI, USA), were prepared in ethanol as
stock solutions (10 mM). T1AM was kindly provided by Dr T.
S. Scanlan (Department of Physiology and Pharmacology,
Oregon Health & Science University, Portland, OR, USA)
and dissolved in 100% ethanol as a stock concentration
(100 mM). All other chemicals and reagents were from Sigma
Chemical Co. (St. Louis, MO, USA).
Results
The potency of T1AM in inhibiting the activity of purified
soluble F1-ATPase, which retains only reverse ATPase activity,
was first evaluated and compared with that of resveratrol.
Based on the IC50 values observed, the inhibitory potency of
T1AM was similar to that of resveratrol (Figure 1A and B). The
reversibility of T1AM inhibition was also demonstrated by
precipitating F1-ATPase and washing it in the absence of
T1AM; samples that were inhibited up to 60% by T1AM
subsequently recovered the same hydrolytic activity as
control samples (data not shown).
Molecular docking analyses were then performed to
predict the T1AM binding locations within the F1-ATPase
structure, whereby different target structures of the protein
were analysed. Docking simulations with T1AM were first
performed using the crystallographic structures of the
enzyme inhibited by two well-characterized inhibitors (the
antibiotic aurovertin B and the natural inhibitor protein IF1)
in addition to the phytochemical resveratrol. Binding regions
are shown in Figure 2B–D. The crystallographic structures of
aurovertin B-inhibited (pdb id. 1COW), resveratrol-inhibited
(pdb id. 2JIZ) and IF1-inhibited (pdb id. 2V7Q) F1-ATPase were
considered following removal of the inhibitor. This approach
enabled us to assess whether T1AM could fit into known
binding cavities. Docking simulations, starting from the
F1-ATPase ground state (pdb id. 1H8E), were performed in
order to confirm whether binding occurred to the known
inhibitory regions and provide clues with regard to other
possible binding sites. The rigid structure of the target most
likely results in non-optimal binding because conformation
rearrangements are not allowed.
The shortest distances between the centre of mass of
aurovertin B, resveratrol and T1AM and the centre of mass of
each of the two inhibitors, resveratrol and aurovertin B,
found in a pose for all the different F1-ATPase target confor-
mations, are reported in Table 1. It should be noted that these
distances depend on the starting target conformation. For
both aurovertin B and resveratrol, poses with the same
overlap in the known binding sites were found for the
inhibited-enzyme complexes with the respective inhibitors
removed. Confident results were obtained only after raising
the exhaustiveness of the docking search in Vina (see
Methods). With the same target structures, poses for T1AM
were found within both aurovertin B and resveratrol binding
sites (Figure 2B and C respectively). In poses in which the
ground state structure was a target, the centre of mass dis-
tances between the known inhibitor sites and each of the
inhibitors were greater. The maximum number of F1-ATPase
common atoms contacted by each chemical inhibitor and IF1
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Figure 1
Effect of T1AM and resveratrol on F1-ATPase activity. F1-ATPase was
incubated with T1AM (7.8–52 mM) or resveratrol (2–52 mM), and
ATPase activity was assayed. In panel A, results are expressed as
percentage residual activity and are means ( SD) of four and five
independent experiments for T1AM and resveratrol, respectively.
Control F1-ATPase activity was 87.4  2.4 mmol ATP hydrolysed
min-1(mg protein)-1 and was set as 100%. In panel B, the IC50 values
for both inhibitors are shown. The values are expressed as both mM
and mmol (mg F1-ATPase)-1.
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found in a pose for all the different target structures is also
reported in Table 1. Overlap with the IF1 binding site was
found in poses that started from all target conformations,
except for the IF1-inhibited complex, suggesting that this
region could be bound by T1AM with no conformational
rearrangements.
To emphasize the overlap between the T1AM and IF1
binding locations, T1AM is shown as van der Waals spheres in
Figure 2D, together with IF1 (dark blue cartoon) and F1
(cartoon coloured by chain). The poses closer to the aurover-
tin binding site were also those with the largest overlap with
the IF1 binding site.
The inhibitory effect exerted by T1AM was further ana-
lysed on the F0F1-ATP synthase whole enzyme complex in
mitochondrial membranes. First, the effect of T1AM on
ATPase-synthase activity was assayed on type II SMP obtained
in the presence of succinate using a standard protocol (Fer-
guson et al., 1977). Considering the T1AM inhibitory effect
on respiratory chain observed in rat liver (Venditti et al.,
2011), in order to minimize ATP synthesis inhibition not due
to direct interaction with the enzyme, T1AM inhibitory
potency upon ATP synthase activity was evaluated supplying
succinate to sustain Dy. In muscle, in contrast to liver mito-
chondria, the complex II substrate is known to sustain respi-
Figure 2
Molecular docking of T1AM into aurovertin B, resveratrol and IF1 binding sites of F1-ATPase. The chemical structure of T1AM consisting of one
phenolic ring and one 3-iodophenylethylamine ring is shown in panel A, Three hypothetical T1AM binding locations within the F1-ATPase structure
obtained by the docking analysis approach (Autodock Vina) are shown in panels B, C and D. In panel B, the aurovertin B binding region is shown;
F1 is shown as a red (B chain, a subunit) and green (F chain, b subunit) cartoon, aurovertin is in blue, the T1AM molecule is in yellow, and F1
residues contacting aurovertin and/or T1AM are in ball and stick format (coloured by atom type). In panel C, the resveratrol binding region of
F1 and the partial overlapping of T1AM is shown; F1 is in cartoon coloured by chain, resveratrol is in blue and the T1AM molecule in yellow. In
panel D, the overlap between the IF1 binding site and the T1AM binding region is shown; T1AM is shown as van der Waals spheres (coloured by
atom name) together with IF1 (dark blue cartoon) and F1 (cartoon coloured by chain).
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ration with lower efficiency than those of complex I (see
Gnaiger, 2009). We confirmed in separate control experi-
ments on permeabilized heart-derived cells, this difference in
efficiency: the values of ADP-stimulated respiration were 131
 21.8 pmol (106 s)-1 for complex I and 45.1  19.5 pmol
(106 s)-1 for complex II. Thus, in the presence of succinate,
T1AM was able to produce minor effects on respiratory com-
plexes (Venditti et al., 2011). The IC50 values (28.2  2.4 mM)
indicate that the inhibitory potency of T1AM upon ATP syn-
thase activity is similar to that of resveratrol (29.9  1.7 mM)
(Figure 3A and B). Conversely, when Dy was reduced by
rotenone, T1AM exerted a very low inhibitory effect upon
ATPase activity (starting at 50 mM inhibitor) that did not
allow us to calculate the IC50 value (Figure 3A). The IC50 of
resveratrol in type II SMP upon ATPase activity (monitored as
a control) was 20.1  0.4 mM (Figure 3B), similar to its
potency upon ATP synthase activity (29.9  1.7 mM), in
accordance with Zheng and Ramirez, (2000). This apparent
discrepancy may be due in part to some inhibitory effect that
T1AM may elicit on the electron transport system.
Nevertheless, we also hypothesized that IF1 bound to the
enzyme could affect the inhibitory action of T1AM but not of
resveratrol on ATPase activity, in line with the overlap
between the T1AM and IF1 binding locations observed by
molecular docking. To test this hypothesis, the inhibitory
potency of T1AM was evaluated on F1-ATPase upon treatment
with IF1 concentrations in the range of the IC50. As shown in
Figure 4, activation of IF1-inhibited F1-ATPase occurs after
treatment with T1AM starting from 50 nM, and is more
evident at higher IF1 concentration (50% inhibition), proving
that T1AM binds with high affinity to F1-ATPase and favours
IF1 displacement. Interestingly, a statistically significant
inhibitory effect by T1AM per se starts to be recorded only at
350 nM. The inhibitory potency of T1AM, compared with
resveratrol, against ATPase activity was also evaluated in par-
ticles with different IF1 contents, i.e. IF1-rich type I SMP and
IF1-stripped ASp. IF1 quantities were determined by immuno-
blot analysis, showing that type I SMP contained an IF1 quan-
tity approximately double that of type II SMP, while ASp
contained negligible amounts of IF1 (Figure S1). The effect of
T1AM was analysed over a large range of concentrations. As
observed for soluble F1-ATPase, activation of the whole
enzyme is elicited in type I SMP in the low nanomolar range
of T1AM (Figure 5, inset panel A). A significant activation was
not observed on type II SMP probably as consequence of the
lower amount of IF1 bound in the enzyme, together with
limits in sensitivity of the spectrophotometric assay. On the
Table 1
Autodock Vina docking analysis data
Target
Distance from aurovertin site Distance from resveratrol site Overlap with IF1 site
Aur Resv T1AM Aur Resv T1AM Aur Resv T1AM
F1 ground state 13.9 Å 15.7 Å 5 Å 5.6 Å 2.3 Å 11.8 Å 20 0 9
F1-IF1 14.6 Å 14.5 Å 17.8 Å 6.1 Å 8.6 Å 12.3 Å 5 5 0
F1-resv 14.0 Å 15.6 Å 11.5 Å 5.9 Å 0.2 Å 1.1 Å 0 0 10
F1-aur 0.5 Å 31.3 Å 4.9 Å 6.2 Å 1.4 Å 1.0 Å 10 0 7
Rows indicate the target structure used for docking. In the first three columns, the shortest distance (among the best nine poses) between
each ligand’s centre of mass, that is aurovertin (aur), resveratrol (resv), T1AM (T1AM) and the centre of mass of aurovertin in complex with
F1, are shown. In the next three columns, the same distances are reported from the centre of mass of resveratrol in complex with F1. In the
last three columns, the maximum number of atoms contacting the three ligands (among the best nine poses) at the IF1/F1 interface is shown.
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Figure 3
Effect of T1AM and resveratrol on the F0F1-ATPase/synthase activity in
type II SMP. Type II SMP were incubated at pH 7.4 with T1AM
(1–90 mM) or with resveratrol (5–60 mM), and ATPase or ATP synthase
activity was assayed as described in the Methods section. In panel A,
ATPase and ATP synthase activities after treatment with T1AM are
shown expressed as percentage residual activity. In panel B, ATPase
and ATP synthase activities after treatment with resveratrol are shown
expressed as percentage residual activity. Data are expressed as
means ( SD) of at least three independent experiments.
BJP3-iodothyronamine binding to F0F1-ATP synthase
British Journal of Pharmacology (2012) 166 2331–2347 2337
contrary, an inhibitory effect was observed with type II SMP
after treatment with micromolar T1AM, although the IC50
value could not be calculated from this slight inhibition
(Figure 5A). The IC50 value of T1AM against whole enzyme in
membrane was calculated in IF1-stripped ASp to be 73.7 
4 mM (Figure 5C). These data confirm our hypothesis that the
presence of IF1 bound in F0F1-ATP synthase influences the
effect of T1AM, suggesting a competition between IF1 and
T1AM for binding to F0F1. This does not occur in the case of
resveratrol, as expected on the basis of the similar IC50 values
for ATPase and ATP synthase activity in type II SMP and the
low frequency of common contacts with IF1 in the docking
analyses. In fact, the IC50 values in type II SMP, type I SMP and
ASp were 20  0.8, 19.1  1.5 and 21.2  1.2 mM respectively
(Figure 5C). In summary, the dual effect exerted by T1AM
may be consistent with the presence of distinct binding
locations, as suggested by docking analysis, with different
affinities.
To further confirm our hypothesis that T1AM binding
leads to the displacement of IF1, IF1 content was quantified by
immunoblotting in IF1-rich type I SMP after treatment with
T1AM (at 0.4–150 mM). Both resveratrol and aurovertin B
were used as controls (Figure 6A and B). This approach
allowed us to monitor a progressive decrease in residual IF1
quantities (i.e. an increase in IF1 release) as T1AM concentra-
tions increased (Figure 6C), showing an asymptotic trend. IF1
release occurring in this assay even at micromolar T1AM
concentration is likely to be due to the experimental proce-
dure, that is SMP sedimentation and supernatant removal.
Conversely, treatment with aurovertin B or resveratrol at con-
centrations close to the IC50 values only slightly reduced
(around 30%) or had no effect upon IF1 content (Figure 6B),
indicating that the experimental procedure affects the
binding equilibrium provided that the binding is destabi-
lized. Together, these data confirm that IF1 is displaced by
T1AM via its high-affinity binding to the enzyme, in accord-
ance with a possible binding location for T1AM lying within
the IF1 binding region as observed by molecular docking.
Of note, the inhibitory potency of T1AM against
F1-ATPase is close to that of resveratrol (Figure 1A and B) and
similar to that observed in ASp (Figure 5C), and no inhibition
was registered after incubation with low concentrations of
T1AM up to 0.25 mM (Figure 4), in accordance with the
absence of IF1 in F1-ATPase preparations. Thus, the F1-ATPase
model was used to characterize the inhibition exhibited by
T1AM at micromolar concentrations and to explore the
localization of the T1AM inhibitory region/site by multiple
inhibitor competition analysis.
As shown by Lineweaver–Burk plots of F1-ATPase activity
at different ATP concentrations (0.125–4 mM), T1AM exerted
non-competitive inhibition (Figure S2A), whereas control
experiments confirmed a mixed type inhibition for resvera-
trol (Figure S2B). The Km at different concentrations of
T1AM, calculated as the intercept of each plot with the x
-axis, was found to be unchanging: 0.69  0.03 mM. The
apparent Vmax was 152.5  2.1 mmol of ATP hydrolysed
min-1 mg-1 in the absence of T1AM and reduced to 96.1  2.8
and 64.9  2.4 mmol ATP in the presence of 18 and 35 mM of
T1AM respectively. The Ki, an index of the inhibitory potency
of T1AM, was calculated using the vi/v0 ratio over the con-
centration range of T1AM (7.8–52 mM) and found to be 29.8
 3.0 mMwhich is compatible with the IC50 value (Figure 1B).
Furthermore, competition experiments using T1AM with
multiple inhibitors were performed as reported in Gledhill
and Walker (2005). The combination of T1AM with IF1, res-
veratrol or aurovertin B was analysed by means of the
Yonetani–Theorell plot (Yonetani and Theorell, 1964) to
determine whether T1AM competes with these inhibitors in a
mutually exclusive manner. A competition experiment using
resveratrol and piceatannol, performed as a control, con-
firmed the data obtained by Gledhill and Walker (2005),
which indicated that the two polyphenolic phytochemical
inhibitors bind to the same site (data not shown). The com-
petition of T1AM and IF1 was analysed for different concen-
tration ranges based on the respective inhibitory potency,
that is 15–45 nM for IF1 and 5–20 mM for T1AM. The plots of
v0/vi against IF1 (I1) at various concentrations of T1AM (I2) and
vice versa generated a series of parallel straight lines (Figure 7A
and B). These results indicate the mutually exclusive binding
of IF1 and T1AM to F1-ATPase, most likely as a consequence of
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Figure 4
Effect of T1AM on IF1-inhibited F1-ATPase. Soluble F1-ATPase (5.2 nM) was preincubated in the absence or in the presence of IF1 (31 or 96 nM),
and effects of T1AM (50–350 nM) on ATPase activity were assayed. Results are expressed as residual activity and are means ( SD) of three
independent experiments. Control F1-ATPase activity was 95.2  2.7 mmol ATP hydrolysed min-1(mg protein)-1. Statistic significance of the
differences was calculated with Student’s t-test for independent groups: *: P < 0.005 significantly different from T1AM-treated/IF1-untreated
correspondent samples. #: P < 0.05 significantly different from T1AM-untreated/IF1-untreated controls. †: P < 0.005 significantly different from 31
or 96 nM IF1-treated/T1AM-untreated correspondent samples.
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partially overlapping binding sites or the distortion of recip-
rocal sites induced by T1AM-F1-ATPase or IF1-F1-ATPase
complex formation. Competition data are in accordance with
IF1 displacement and with a possible binding location for
T1AM lying within the IF1 binding region as observed by
molecular docking analyses. The inhibitory effect that IF1 was
still able to achieve despite micromolar concentrations of
T1AM (Figure 7A and B) could be explained by the hypothesis
that T1AM binding to the low affinity region/site reduces the
negative control exerted by the high-affinity region/site on
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Figure 5
Effect of T1AM and resveratrol on F0F1-ATPase activity in type I SMP, type II SMP and ASp containing different amounts of IF1. Type I SMP, type
II SMP and ASp were incubated with T1AM or resveratrol, and ATPase activity was assayed. Panel A shows the plot of the ATPase activity (as
mmol·min-1·mg-1) of SMP I and SMP II against 0.025–150 mM T1AM concentration (n = 4). In the inset, the range between 0.025 and 0.2 mM
T1AM is enlarged; * P< 0.05, significant activation of ATPase. Panel B shows the plot of the ATPase activity of SMP I and SMP II against 0.05–35 mM
resveratrol concentration (n = 4). The plots in panel C report ATPase activity of ASp against resveratrol (0.5–35mM) and T1AM (0.025–90 mM) (n
= 3). Dotted lines indicate the IC50 values of resveratrol on SMP I and SMP II (panel B) and of both resveratrol and T1AM on ASp (panel C). Control
F0F1-ATPase activity was 2.5  0.3 mmol ATP hydrolysed min-1(mg protein)-1 (n = 3) for type I SMP, 4.9  0.3 mmol ATP hydrolysed min-1(mg
protein)-1 (n = 3) for type II SMP, and 13.0  0.4 mmol ATP hydrolysed min-1(mg protein)-1 (n = 3) for ASp. Data shown are means  SD.
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IF1 binding, as also suggested by the data shown in Figures 4
and 5.
The Yonetani–Theorell plot obtained for T1AM and
aurovertin B gave a series of parallel lines (Figure 7C), again
indicating the mutually exclusive binding of T1AM to
F1-ATPase, in line with overlapping of the T1AM and aurover-
tin B binding locations as revealed by molecular docking
analyses. Intersecting lines were observed in a similar plot for
T1AM with resveratrol (Figure 7D), indicating that the two
compounds bind to different sites, contrary to what sug-
gested by the modelling data.
Finally, to further corroborate the activating effect elicited
by T1AM on F0F1-ATP synthase, we investigated if such an
effect was observed on mitochondrial ATP synthesis under
more physiological conditions, i.e. in whole cells. In situ
respirometric analysis was performed on H9c2 cardiomyo-
cytes at low nanomolar concentrations of T1AM. An increase
in ADP-stimulated mitochondrial respiration with no effect
on resting respiration was observed, indicating an activation
of F0F1-ATP synthase. A representative experiment carried out
at 50 nM T1AM is shown in Figure 8. In order to estimate the
molar ratio between endogenous IF1 and the putative com-
petitor T1AM added to permeabilized cells, we quantified IF1
content by quantitative immunoblotting on H9c2 total
homogenates, using a calibration plot with purified IF1 as a
standard (Figure S3). The value of IF1 content obtained was
2.04  0.36 pmol mg-1, that is equivalent to about 2 mM. This
is considerably in excess of the concentration iof T1AM
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Figure 6
Quantification of IF1 in IF1-rich Type I SMP after treatment with inhibitors. Type I SMP were pre-incubated in the absence or presence of different
concentrations of T1AM, resveratrol or aurovertin. IF1 displaced from F0F1-ATP synthase was removed by ultra centrifugation of the supernatant
and the SMP sediment resuspended in medium without inhibitors. Panel A shows a representative image of the immunoreactive bands relative
to different quantities of protein separated by SDS-PAGE, transblotted and identified with specific antibodies against the F0F1-ATP synthase b
subunit and IF1. The concentrations of the inhibitors in the experiment shown were as in panel B, except for T1AM which was used at 150 mM.
In panel B, quantitative data inferred by densitometric analysis of immunoreactive bands are summarized. Values are expressed as percentages.
IF1 was normalized to F0F1-ATP synthase b subunit (b) quantities, as described in the Methods section, with the IF1/b ratio of untreated control
samples considered as 100%. Values are means ( SD) of at least three independent experiments. Panel C shows the plot of IF1/b (%) against
T1AM concentration (0.4–150 mM). The inset shows an enlargement of the change in IF1 amounts at the lowest T1AM concentrations.
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added (50nM) so our results showing activation of mitochon-
drial ATP synthesis suggest that the mitochondria may have
concentrated T1AM. At about 6 mM, T1AM should be able to
compete with IF1, on the basis of threefold excess of competi-
tor required in vitro, as indicated by Figures 4 and 5. Thus, our
data indicate that T1AM can be concentrated inside H9c2
mitochondria without reaching, under the experimental con-
ditions used, an ATP synthase-inhibiting concentration (see
data reported in figure 3A).
Discussion
F0F1-ATP synthase plays a critical role in both human health
and disease and it represents a promising therapeutic target
for the treatment of diseases, such as cancer, diabetes, heart
disease, mitochondrial myopathies, neurodegenerative dis-
eases and immune disorders (see Hong and Pedersen, 2008;
Lippe et al., 2009; Johnson and Ogbi, 2011). Thus, a better
understanding of F0F1-ATP synthase inhibition and regulation
may aid the treatment of these diseases.
T1AM is a novel endogenous chemical messenger formed
during thyroxine metabolism (Scanlan et al., 2004), which
has been found in vivo in several tissues of mouse and rat, as
well as in human blood (Galli et al. 2012). Its intracellular
concentration exceeds that of tri-iodothyronine (T3) by about
10-fold in most tissues, including the heart (Saba et al., 2010).
Non-genomic effects of thyroid hormone-related compounds
have been known for a long time; nevertheless, the molecules
and mechanisms that trigger such effects have not been com-
pletely elucidated. There is already evidence that T1AM may
mediate such effects (Ianculescu and Scanlan, 2010; Fras-
carelli et al., 2011) and T1AM deserves particular attention as
it does not interact with thyroid hormone receptors, but
rather with membrane GPCRs and possibly with intracellular
binding sites (Scanlan et al., 2004; Piehl et al., 2011).
The effects of thyroid hormone and its derivatives on
mitochondrial energy production, as well as the finding that
intracellular transport (Ianculescu et al., 2009) gives T1AM
access to mitochondrial targets (Frascarelli et al., 2011),
prompted us to investigate T1AM interaction with F0F1-ATP
synthase in vitro. As T1AM was shown here to interact with
F0F1-ATP synthase, by exerting a dual effect upon the enzyme
activity, the range of endogenous compounds known to bind
to and regulate F0F1-ATP synthase is extended.
Because of the physiological and pathological roles
exerted by IF1 in F0F1-ATP synthase regulation (Rouslin et al.,
1995; Green and Grover, 2000; Contessi et al., 2004; Penna
et al., 2004; Comelli et al., 2007), the IF1-displacing effect of
T1AM is an intriguing result and is reinforced by the data
from the molecular docking analyses, which suggest that
T1AM may bind within the IF1 binding cavity, related by
approximate symmetry to the aurovertin binding site. The
overlap of T1AM docking with the IF1 binding site was found
in poses arising from all the target starting conformations
of the enzyme except the IF1-inhibited (i.e. resveratrol-
inhibited, aurovertin B-inhibited and ground state
F1-ATPase), suggesting that the binding of T1AM within the
IF1 binding region likely occurs with negligible conforma-
tional rearrangements. The biochemical approaches allowed
us to demonstrate that the binding of T1AM to F0F1-ATP
synthase did actually occur and was mutually exclusive with
the binding of IF1. These conclusions were based on the
following findings: (i) the effects of T1AM on the ATPase
activity observed with IF1-inhibited F1ATPase and different
IF1-containing particles; (ii) the results of immunodetection
of the residual IF1 content of the particles upon exposure to
T1AM; and (iii) the results of T1AM–IF1 competition analyses.
From these results, we can confidently state that when T1AM
binds to the F1 sector at low nanomolar concentrations, it
favours the release of IF1 from its binding site, which is
located on a catalytic interface between the C-terminal
regions of the aDP- and bDP- subunits. Hence, we named the
T1AM high affinity-binding site as ‘IF1-displacing high-
affinity site’.
Based on the IF1-displacing effect shared by T1AM and the
antibiotic aurovertin B (Johnson et al., 2009), we performed
docking analyses and compared their inhibitory effects.
Figure 8
Effect of T1AM upon ADP-stimulated mitochondrial respiration of digitonin-permeabilized H9c2 cells. Representative oxygen flow records
(high-resolution respirometer Oxygraph 2k) are reported for cells pre-incubated with 50 nM T1AM and control samples. Respiratory rates
sustained by complex I were measured in two metabolic states – resting respiration and ADP-stimulated respiration. Metabolic substrates (G,
glutamate, M, malate; and ADP; in blue) were added to the chamber at concentration specified in Methods. Analysis sections (in red) were marked
when signal stability was reached. One experiment representative of three (SD < 18%).
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Aurovertin B is known to bind to F1-ATPase and to occupy a
cavity situated on the cleft between the nucleotide-binding
and C-terminal domains of the b-subunits, as depicted by
crystallographic data (van Raaij et al., 1996). Docking analy-
ses for the T1AM molecule performed in the aurovertin B
binding cavity of all the above mentioned F1-ATPase inhib-
ited structures depleted of inhibitor, as well as in the ground
state structure, suggested that a T1AM binding site could be
located within the aurovertin B binding cavity. Kinetic
experiments revealed that (i) T1AM bound with a low affinity,
thereby eliciting inhibitory effects (micromolar range); and
(ii) its binding appeared to be mutually exclusive with that of
aurovertin B. Thus, T1AM may bind within the aurovertin B
binding site. In line with results observed at micromolar
concentration on type II SMP, the inhibitory effects of T1AM
on ATPase activity may well be counteracted by T1AM
binding to the ‘IF1-displacing high-affinity site’. Indeed, IF1
release caused an increase in the amount of active ATPase
molecules, thereby making ligand concentration limiting.
Accordingly, no inhibitory effect was observed with IF1-rich
type I SMP, where at low T1AM concentrations, an activating
effect indicative of IF1 release was observed and the two
effects are apparently balanced. Hence, we postulated a
second T1AM binding site and we named it as ‘aurovertin-
displacing low affinity-site’.
Of note, T1AM appears to be a significantly more potent
inhibitor of ATP synthesis than ATP hydrolysis. This may be
partially a consequence of T1AM inhibition of complex III of
the respiratory chain, which as been recently reported (Ven-
ditti et al., 2011). Nevertheless, as similar differential effects
were reported for aurovertin (Lenaz, 1965; Lee and Ernster,
1968; Roberton et al., 1968; Bertina et al., 1973), an alterna-
tive explanation may be that previously suggested for
aurovertin (Johnson et al., 2009). These authors showed that
aurovertin elicited a paradoxical activating effect of ATP
hydrolysis at low concentrations of substrate, which was con-
nected to dissociation of IF1 from the F1 domain. This hypoth-
esis was confirmed in the present study by immunoblotting
analysis documenting a significant release of IF1 from F0F1-
ATP synthase, following treatment of IF1-rich type I SMP with
aurovertin. Notably, this effect was smaller than that
observed with T1AM and in accordance with the finding that
aurovertin exerted similar inhibitory effects on IF1-free
F1-ATPase and IF1-containing SMP particles (Hong and Peder-
sen, 2008).
In line with the IF1-displacing effect shared by T1AM and
aurovertin B and the proximity of the aurovertin B and IF1
sites defined by crystallography (van Raaij et al., 1996;
Cabezon et al., 2003), we suggest a reciprocal influence
between the T1AM binding sites. Thus, the activation
exerted by T1AM on IF1-inhibited F1-ATPase and IF1-rich type
I SMP at low nanomolar but not at higher concentrations
can be explained by the hypothesis that T1AM binding to
the low affinity region/site reduces the negative control
exerted by the high-affinity region/site on IF1 binding. Such
a mutual interaction between the two sites also justifies the
mutual exclusive binding of IF1 and T1AM at micromolar
concentrations.
Many polyphenols have been shown to bind to and
inhibit F0F1-ATP synthase, and the potentially relevant effects
of natural dietary polyphenolic compounds as antimicrobial
and anti-tumour agents are proposed to be partly linked to
the inhibition of ATP synthesis (Pirola and Frojdo, 2008). The
polyphenol binding pocket is well known and is located
between the tip in the C-terminal region of the g subunit and
the bTP subunit (Gledhill et al., 2007a). Although our model-
ling analysis, performed by docking the T1AM molecule into
the three F1-ATPase inhibited structures, also suggests the
resveratrol site as a putative location for T1AM, the compe-
tition experiments indicated that resveratrol and T1AM
binding are not mutually exclusive. Thus, the possibility that
T1AM may bind to the resveratrol site can be excluded.
Representation of T1AM binding regions in
F0F1-ATP synthase structure
The binding regions of the three known inhibitors in the
F1-ATPase structure are depicted in Figure 9; three putative
T1AM locations are denoted by circles. These binding regions
may be consistent with the particular dual effect elicited by
T1AM, as demonstrated by our data, as well as with mutual
influence between the sites. As mentioned above, docking
analyses suggest that the aurovertin B site is a possible
binding site for T1AM. Poses were found in the experimental
cavities revealed by X-ray crystallography and also in a region
overlapping the IF1 binding site, which is approximately
symmetry-related to the two aurovertin binding sites. Thus,
considering the proximity of the aurovertin B and IF1 sites
defined by crystallography (van Raaij et al., 1996; Cabezon
et al., 2003), we suggest that the T1AM ‘IF1-displacing high-
affinity site’ could be either the site overlapping with IF1
related by approximate symmetry with aurovertin binding
sites, or one of the two aurovertin binding sites, even as one
of these could be T1AM ‘aurovertin-displacing low affinity-
site’. A reciprocal influence between the T1AM putative
binding sites is suggested by the similarity of behaviour of
T1AM and aurovertin.
Nevertheless, the higher IF1-displacing efficiency of T1AM
with respect to aurovertin B, together with T1AM proximity
(docking analysis) to IF1 residues 1–7, which are reported to
contribute to the destabilization of the binding of IF1 to F1
(Bason et al., 2011), allows us to hypothesize that the T1AM
‘IF1-displacing high-affinity site’ most likely overlaps with the
IF1 binding site.
Considerations on physiopathological or
pharmacological impact
T1AM is an endogenous compound that has been detected in
many different tissues. In rat, the highest T1AM levels were
observed in liver, brain and kidney, where overall T1AM con-
centration ranged from 36 to 93 pmol g-1 (i.e. around 40–90
nM) (Saba et al., 2010). The effects elicited on intact mito-
chondria indicated that it can enter mitochondria (Venditti
et al., 2011). On the basis of our findings, we suggest that the
effect of T1AM binding, impairing IF1 inhibitory efficiency,
could be of physiological or pathological relevance, and that
endogenous T1AM may represent another endogenous factor
(in addition to pH, Dm+ and ATP, Ca2+ and Mg2+ levels)
involved in the modulation of the steady-state binding of IF1
to F0F1-ATP synthase. Such effects may be particular relevant
in the heart, where recent experiments have shown that
T1AM reaches a concentration (6.6 pmol g-1, i.e. around
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10 nM) 20-fold higher than that in the extracellular compart-
ment both in vivo and ex vivo. Accordingly, isolated cardio-
myocytes are able to take up exogenous T1AM, establishing a
30-fold gradient between intracellular and extracellular con-
centration (Saba et al., 2010).
In whole cells, using in situ respirometric analysis on H9c2
cardiomyocytes treated with T1AM at a concentration in the
order of 50 nM, we observed an increase of ADP-stimulated
respiration, indicating an activation of mitochondrial ATP
synthesis and suggesting a positive effect of T1AM upon the
steady-state mitochondrial energy production. Such an acti-
vating effect is ascribed to IF1 release from F0F1-ATP synthase
and is consistent with that obtained by IF1-stripping treat-
ment (alkaline pH and high saline concentrations) of mito-
chondria isolated from this cell line (Comelli et al., 2007). In
vivo activation, corresponding to an increase in ATP synthase
molecules available for synthesis, was previously reported as
being related to IF1 release by different triggers, such as elec-
trical stimulation of cardiomyocytes (Das and Harris, 1990)
and cardiac reactive hyperaemia (Di Pancrazio et al., 2004;
Penna et al., 2004). It should be noted that the IF1 content in
H9c2 cells was estimated to be around 2 mM, which is not far
from data reported by Giorgio et al. (2010) and is well in
excess of the T1AM concentration in our experiments
(around 50 nM). It was thus likely that T1AM can be concen-
trated inside H9c2 mitochondria, as found for cells (Saba
et al., 2010). The subcellular distribution of T1AM remains to
be clarified and it is possible that its concentration in specific
compartments such as mitochondria may be significantly
different from the average concentrations that have been
measured so far (Saba et al., 2010; Zucchi et al., 2010). In
conclusion, in the light of our data, endogenous T1AM levels
may be able to contribute to the regulation of the steady-state
binding of IF1 to F0F1-ATP synthase. Of note, based on the low
level of bound IF1 observed in H9c2 cardiomyocytes (Comelli
et al., 2007) and the correlation with heart rate (Rouslin et al.,
1995), a more pronounced effect may be expected in low
heart rate mammalian species containing high IF1 levels
(Rouslin et al., 1995; Di Pancrazio et al., 2004). Nevertheless,
the physiological implications of our findings require further
investigations.
It is not clear whether the inhibitory effect of T1AM upon
ATP synthase activity which requires micromolar concentra-
tions, would have a physiopathological or pharmacological
role. Nevertheless, some systemic effects of T1AM have been
reported to occur at micromolar concentrations (Chiellini
et al., 2007), which could correspond to putative therapeutic
doses of T1AM. Of note, there is convincing evidence that
down-modulation of ATP synthase afforded by the benzodi-
azepine derivative Bz-423 results in selective killing of
autoimmune lymphocytes and alloreactive T cells through
activation of apoptotic signalling (Gatza et al., 2011; Johnson
and Ogbi, 2011). Designing a pharmacological strategy to
target the ATP synthase with a natural compound such as
T1AM may extend the reange of therapies for autoimmune
and immune disorders.
The potential beneficial contribution of ATP synthase
inhibition to the protection of the ischemic heart by T1AM
appears to be counterintuitive and needs obviously further ad
hoc investigation. Distinct mechanisms may be involved in
T1AM cardioprotection, and they have only partially been
Figure 9
Putative T1AM binding regions that overlap with the IF1, aurovertin
B but not resveratrol binding sites in F1-ATPase. The side view of the
F1-ATPase structure and the view along the central axis from the
catalytic sites towards the membrane are shown. IF1 (red, van der
Waals spheres), aurovertin B (yellow, van der Waals spheres) and
resveratrol (blue, van der Waals spheres) inside their respective
binding sites are shown (structures from Protein Data Bank). T1AM
binding regions predicted using the Autodock Vina program (Trott
and Olson, 2010) and confirmed by kinetic data are indicated by
circles (white circle indicate the site overlapping with IF1 binding site;
black circles indicate the sites overlapping with aurovertin binding
sites). Images were produced using the program Visual Molecular
Dynamics (Morris et al., 2009). Based on the model depicted, the
so-called IF1-displacing high-affinity site of T1AM could be either the
site overlapping with IF1 related by approximate symmetry with
aurovertin binding sites, or one of the two aurovertin binding sites,
which could correspond to the so-called aurovertin-displacing low
affinity-site.
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elucidated, although pharmacological evidence suggests a
potential role of mitochondrial effects (Frascarelli et al.,
2011). In principle, T1AM treatment may transiently limit
ATP synthesis at the onset of reperfusion, when an increase in
ATP concentration occurs and paradoxically contributes to
reperfusion injury, leading to hyper-contracture of cardio-
myocytes, membrane disruption and subsequent necrosis
(Piper et al., 2004). Thus, T1AM may reduce the risk of devel-
oping myocardial hypercontracture, which seems to be a
major mechanism of early reperfusion-induced cell death.
However, excessive inhibition of ATP synthesis would obvi-
ously be detrimental. Therefore, T1AM administration should
be carried out after thorough consideration of the relevant
potential side effects linked to excessive energy impairment.
On the other hand, it should call attention to a paradoxical
effect that may be elicited on F0F1-ATP synthase working in
ATPase-mode in the ischemic heart by T1AM-mediated IF1
release, if any. It is relevant to note that in states of compro-
mised ATP production, such as prolonged ischemia, IF1 may
lose effectiveness because reduced ATP and supraphysiologi-
cal levels of Ca2+ and Mg2+ favour IF1 release from F0F1-ATP
synthase, thereby suppressing the energy–sparing, endog-
enous, protective mechanism. Under such conditions, in
which ATP hydrolysis prevails, the inhibitory effects of T1AM
may be more relevant, as shown in vitro on IF1-free ASp, and
represent an alternative mechanism for minimizing ATP loss.
Finally, the use of T1AM as an F0F1-ATP synthase-directed
agent might have some side-effects. There is now convincing
evidence that T1AM is a chemical messenger with widespread
effects, ranging from metabolic regulation to neuromodula-
tion, to the control of insulin and glucagon secretion, and
possibly to behavioural effects. Therefore, administration of
exogenous T1AM, or interference with T1AM metabolism,
should be carried out with great care.
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